Head-To-Head Review: Carpenter Technology (NYSE:CRS) and Mainz Biomed (NASDAQ:MYNZ)

Carpenter Technology (NYSE:CRS) and Mainz Biomed (NASDAQ:MYNZ) are both industrials companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

92.0% of Carpenter Technology shares are owned by institutional investors. 2.9% of Carpenter Technology shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Carpenter Technology and Mainz Biomed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carpenter Technology	$3.12 billion	6.29	$529.80 million	$10.52	37.72
Mainz Biomed	$659,935.00	18.81	-$21.65 million	($65.60)	-0.02

Carpenter Technology has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Carpenter Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Carpenter Technology and Mainz Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carpenter Technology	16.96%	26.46%	15.02%
Mainz Biomed	N/A	N/A	N/A

Volatility & Risk

Carpenter Technology has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Carpenter Technology and Mainz Biomed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carpenter Technology	0	2	8	0	2.80
Mainz Biomed	1	1	0	0	1.50

Carpenter Technology presently has a consensus price target of $577.25, indicating a potential upside of 45.48%. Given Carpenter Technology’s stronger consensus rating and higher possible upside, research analysts plainly believe Carpenter Technology is more favorable than Mainz Biomed.

Summary

Carpenter Technology beats Mainz Biomed on 12 of the 14 factors compared between the two stocks.

About Carpenter Technology

Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves to aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.